Publications by authors named "K S Viola"
Background: Many adults aged 60 years or older have functional limitations and require home and community-based services (HCBS) to support their independence and delay the transition to an institutionalized setting. This systematic review provides an evidence map of the existing literature on HCBS identifying evidence gaps for policy and research.
Methods: A comprehensive literature search of multiple databases including Medline, Embase, and Scopus was conducted through December 7, 2023.
Article Synopsis
- The Health Information Technology for Economic and Clinical Health Act led to a rise in electronic health record (EHR) systems, increasing the documentation burden, which affects healthcare professionals' experience and contributes to burnout.
- A systematic review analyzed 135 articles to identify methods for measuring this burden, categorizing them into 11 different areas like overall EHR time, clinical documentation activities, and administrative tasks.
- While various measures exist, they tend to be one-dimensional and may not fully address the complexity of documentation burden, with limited evidence supporting their validity and applicability across different healthcare settings.
Numerous Aβ proteoforms, identified in the human brain, possess differential neurotoxic and aggregation propensities. These proteoforms contribute in unknown ways to the conformations and resultant pathogenicity of oligomers, protofibrils, and fibrils in Alzheimer's disease (AD) manifestation owing to the lack of molecular-level specificity to the exact chemical composition of underlying protein products with widespread interrogating techniques, like immunoassays. We evaluated Aβ proteoform flux using quantitative top-down mass spectrometry (TDMS) in a well-studied 5xFAD mouse model of age-dependent Aβ-amyloidosis.
View Article and Find Full Text PDFRationale: Extracellular proteolytic activity plays an important role in memory formation and the preservation of cognitive function. Previous studies have shown increased levels of plasminogen activator inhibitor-1 (PAI-1) in the brain of mouse models of Alzheimer's disease (AD) and plasma of AD patients, associated with memory and cognitive decline; however, the exact function of PAI-1 in AD onset and progression is largely unclear.
Objective: In this study, we evaluated a novel PAI-1 inhibitor, TM5A15, on its ability to prevent or reverse memory deficits and decrease Aβ levels and plaque deposition in APP/PS1 mice.